ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

ClinicalTrials.gov ID: NCT05607550

Public ClinicalTrials.gov record NCT05607550. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 20, 2026, 7:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Study identification

NCT ID
NCT05607550
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
ArriVent BioPharma, Inc.
Industry
Enrollment
398 participants

Conditions and interventions

Interventions

  • furmonertinib 160 mg oral, daily Drug
  • furmonertinib 240 mg oral, daily Drug
  • platinum-based chemotherapy Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2023
Primary completion
Aug 14, 2025
Completion
Feb 14, 2028
Last update posted
Jun 21, 2025

2023 – 2028

United States locations

U.S. sites
69
U.S. states
28
U.S. cities
67
Facility City State ZIP Site status
Arrivent Investigative Site Daphne Alabama 36526
Arrivent Investigative Site Yuma Arizona 85364
Arrivent Investigative Site Fayetteville Arkansas 72703
Arrivent Investigative Site Beverly Hills California 90212
Arrivent Investigative Site Fullerton California 92835
Arrivent Investigative Site Long Beach California 90806
Arrivent Investigative Site Los Alamitos California 90720
Arrivent Investigative Site Napa California 94558
Arrivent Investigative Site Orange California 90868
Arrivent Investigative Site Orange California 92868
Arrivent Investigative site Sacramento California 95817
Arrivent Investigative Site San Diego California 92123
Arrivent Investigative Site Santa Barbara California 93105
Arrivent Investigative Site Santa Monica California 90404
Arrivent Investigative Site Santa Rosa California 95403
Arrivent Investigative Site Whittier California 90602
Arrivent Investigative Site Hartford Connecticut 06102
Arrivent Investigative Site Norwich Connecticut 06360
Arrivent Investigative Site Fort Myers Florida 33901
Arrivent Investigative Site St. Petersburg Florida 33705
Arrivent Investigative Site The Villages Florida 32159
Arrivent Investigative Site Peoria Illinois 61615
Arrivent Investigative Site Rolling Meadows Illinois 60008
Arrivent Investigative Site Fort Wayne Indiana 46804
Arrivent Investigative Site Indianapolis Indiana 46250
Arrivent Investigative Site South Bend Indiana 46601
Arrivent Investigative Site Bethesda Maryland 20817
Arrivent Investigative Site Frederick Maryland 21702
Arrivent Investigative Site Rockville Maryland 20850
Arrivent Investigative Site Fairhaven Massachusetts 02719
Arrivent Investigative Site Lansing Michigan 48912
Arrivent Investigative Site Bolivar Missouri 65613
Arrivent Investigative Site Kansas City Missouri 64111
Arrivent Investigative Site Saint Joseph Missouri 64507
Arrivent Investigative Site St Louis Missouri 63110
Arrivent Investigative Site Omaha Nebraska 68114
Arrivent Investigative Site Belleville New Jersey 07109
Arrivent Investigative Site Englewood New Jersey 07631
Arrivent Investigative Site Florham Park New Jersey 07932
Arrivent Investigative Site The Bronx New York 10461
Arrivent Investigative Site Goldsboro North Carolina 27534
ArriVent Investigative Site Pinehurst North Carolina 28374
Arrivent Investigative Site Canton Ohio 44708
Arrivent Investigative Site Cincinnati Ohio 45220
ArriVent Investigative Site Cincinnati Ohio 45242
Arrivent Investigative Site Cleveland Ohio 44195
Arrivent Investigative Site Columbus Ohio 43214
Arrivent Investigative Site Oklahoma City Oklahoma 73102
Arrivent Investigative Site Tulsa Oklahoma 74146
Arrivent Investigative Site Salem Oregon 97301
Arrivent Investigative Site Gettysburg Pennsylvania 17325
ArriVent Investigative Site Langhorne Pennsylvania 19047
Arrivent Investigative Site York Pennsylvania 17403
Arrivent Investigative Site Greenville South Carolina 29607
Arrivent Investigative Site Sioux Falls South Dakota 57117
Arrivent Investigative Site Memphis Tennessee 38120
ArriVent Investigative Site Nashville Tennessee 37203
Arrivent Investigative Site Abilene Texas 79606
ArriVent Investigative Site Austin Texas 78745
Arrivent Investigative Site Houston Texas 77030
Arrivent Investigative Site Plano Texas 75093
Arrivent Investigative Site Ogden Utah 84405
Arrivent Investigative Site Salt Lake City Utah 84106
ArriVent Investigative Site Fairfax Virginia 22031
Arrivent Investigative Site Fredericksburg Virginia 22408
Arrivent Investigative Site Bellingham Washington 98225
Arrivent Investigative Site Spokane Valley Washington 99216
Arrivent Investigative Site Tacoma Washington 98405
Arrivent Investigative Site Appleton Wisconsin 54911

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 139 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05607550, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 21, 2025 · Synced Apr 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05607550 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →